DE69226197D1 - Hämoglobine als arzneimittelabgabesystem - Google Patents

Hämoglobine als arzneimittelabgabesystem

Info

Publication number
DE69226197D1
DE69226197D1 DE69226197T DE69226197T DE69226197D1 DE 69226197 D1 DE69226197 D1 DE 69226197D1 DE 69226197 T DE69226197 T DE 69226197T DE 69226197 T DE69226197 T DE 69226197T DE 69226197 D1 DE69226197 D1 DE 69226197D1
Authority
DE
Germany
Prior art keywords
hemoglobine
delivery system
medicine delivery
hemoglobin
tracer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69226197T
Other languages
English (en)
Other versions
DE69226197T2 (de
Inventor
David Anderson
Antony Mathews
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapure Biopharma Inc
Original Assignee
SOMATOGEN Inc BOULDER US
Somatogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69226197(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/789,179 external-priority patent/US5545727A/en
Application filed by SOMATOGEN Inc BOULDER US, Somatogen Inc filed Critical SOMATOGEN Inc BOULDER US
Publication of DE69226197D1 publication Critical patent/DE69226197D1/de
Application granted granted Critical
Publication of DE69226197T2 publication Critical patent/DE69226197T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69226197T 1991-11-08 1992-11-06 Hämoglobine als arzneimittelabgabesystem Expired - Lifetime DE69226197T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78917791A 1991-11-08 1991-11-08
US07/789,179 US5545727A (en) 1989-05-10 1991-11-08 DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
PCT/US1992/009713 WO1993008842A1 (en) 1991-11-08 1992-11-06 Hemoglobins as drug delivery agents

Publications (2)

Publication Number Publication Date
DE69226197D1 true DE69226197D1 (de) 1998-08-13
DE69226197T2 DE69226197T2 (de) 1999-02-11

Family

ID=27120889

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69226197T Expired - Lifetime DE69226197T2 (de) 1991-11-08 1992-11-06 Hämoglobine als arzneimittelabgabesystem

Country Status (8)

Country Link
US (2) US5679777A (de)
EP (1) EP0611306B1 (de)
JP (1) JP3426599B2 (de)
AT (1) ATE168014T1 (de)
AU (1) AU665599B2 (de)
CA (1) CA2122717C (de)
DE (1) DE69226197T2 (de)
WO (1) WO1993008842A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
JP3426599B2 (ja) * 1991-11-08 2003-07-14 ヘモゾル インコーポレイテッド 薬物担体としてのヘモグロビン
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0804244A1 (de) * 1993-03-26 1997-11-05 Biorelease Technologies, Inc. Häm-proteine enthaltende zusammensetzungen und dazu gehörende methoden
US5665869A (en) * 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1950298A3 (de) 1997-05-02 2008-12-24 Baxter Biotech Technology S.A.R.L. Hämoglobinmutanten mit erhöhtem Löslichkeitswert und/oder reduzierter Stickoxidspülung
DE69829567T2 (de) * 1997-06-24 2006-02-16 Proteus Molecular Design Ltd., Macclesfield Angiotensinderivate
US7378489B1 (en) 1999-12-23 2008-05-27 Protherics Medicines Development Limited Angiotensin derivatives
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6548540B2 (en) 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6706252B1 (en) 1998-10-30 2004-03-16 Rx/Ibr Corporation Method of treating disease with radioisotopes conjugated to bioactive substances
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
PT1240337E (pt) * 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
WO2001060412A2 (en) 2000-02-15 2001-08-23 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
GB0125793D0 (en) * 2001-10-26 2001-12-19 Panzeri Ezio Method
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7235639B2 (en) 2003-04-23 2007-06-26 Ezio Panzeri Hemoglobin conjugates
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
BRPI0516577A (pt) * 2004-10-05 2008-09-16 Genentech Inc agentes terapêuticos com toxicidade diminuìda
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
EP1858543B1 (de) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor
EP2386571B1 (de) 2005-04-08 2016-06-01 ratiopharm GmbH Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
EP1893632B1 (de) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
DE102006011660A1 (de) * 2006-03-12 2007-09-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Ermittlung einer Dotierungsdichte in einer Halbleiterprobe
EP2049144B8 (de) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US8822639B2 (en) 2006-12-12 2014-09-02 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
EP2192914A4 (de) * 2007-08-20 2014-05-07 Belrose Pharma Inc Polymere linker mit pyridyl-disulfid-resten
MX2010009154A (es) 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
US8436140B2 (en) * 2008-06-02 2013-05-07 Washington University Natriuretic peptide-mediated imaging of atherosclerotic plaque
US20140308260A1 (en) * 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
JP6019126B2 (ja) 2011-10-07 2016-11-02 エピセントアーレックス・インコーポレイテッドＥｐｉｃｅｎｔＲｘ， Ｉｎｃ． 有機ニトロチオエーテル化合物およびその医療用途
JP6329537B2 (ja) * 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
TWI610685B (zh) * 2013-05-13 2018-01-11 視界全球控股有限公司 用於癌症標靶治療及診斷成像之包含經修飾的基於血紅素之治療劑的醫藥組成物
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
PL412787A1 (pl) 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
KR20190040931A (ko) 2016-01-11 2019-04-19 에피센트알엑스, 인코포레이티드 2-브로모-1-(3,3-디니트로아제티딘-1-일)에타논의 정맥내 투여를 위한 조성물 및 방법
WO2017197499A1 (en) * 2016-04-25 2017-11-23 The Governing Council Of The University Of Toronto Stabilized hemoglobin-avidin assembly and method of preparation
WO2017221185A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
EP3526195A4 (de) 2016-10-14 2020-05-20 EpicentRx, Inc. Sulfoxyalkylorganonitro- und verwandte verbindungen und pharmazeutische zusammensetzungen zur verwendung in der medizin
EP3579891A4 (de) * 2017-02-08 2021-01-06 HKL Medical, LLC Intrasite-verabreichungs- und dosierverfahren und arzneimittel zur verwendung darin
BR112020000196A2 (pt) 2017-07-07 2020-07-07 Epicentrx, Inc. composições para administração parenteral de agentes terapêuticos
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
EP3650046A1 (de) 2018-11-08 2020-05-13 Cellis AG System auf basis mesenchymaler stammzellen zur gezielten wirkstoffabgabe
WO2024056413A1 (en) 2022-09-13 2024-03-21 Cellis Ag Isolated targeted delivery system for the treatment of glioma
WO2024133541A1 (en) 2022-12-20 2024-06-27 Cellis Sp. Z O.O. [Ltd.] Isolated targeted delivery system for the treatment of ovarian cancer

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934008A (en) * 1968-08-23 1976-01-20 Ciba-Geigy Corporation N-acyl and desamino human calcitonin and analogs thereof
US3980764A (en) * 1973-11-05 1976-09-14 Curtis Nuclear Corporation Polymeric competitive protein binding adsorbents for radioassey
US4042677A (en) * 1974-08-29 1977-08-16 Union Carbide Corporation Technetium-99m labeled radiodiagnostic agents and method of preparation
DE2449885C3 (de) * 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
DE2843963A1 (de) * 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
EP0039179B1 (de) * 1980-04-28 1985-07-24 National Research Development Corporation Poröses Glas
JPS5716815A (en) * 1980-07-02 1982-01-28 Ajinomoto Co Inc Oxygen transporting agent for artificial blood
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4374932A (en) * 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4500507A (en) * 1981-10-30 1985-02-19 Wong Dennis W Diagnostic composition for radiologic imaging of neoplasms in the body and method of preparation
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
IT1153000B (it) * 1982-07-01 1987-01-14 Resem Spa Dispersioni acquose di poliuretani da oligouretani aventi gruppi terminali insaturi
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4738952A (en) * 1984-04-27 1988-04-19 Synthetic Blood Corporation Substitute for human blood and a method of making the same
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
EP0210204B1 (de) * 1985-01-18 1988-12-07 Kailash Kumar Dr. Prof. Gauri Proteinhydrolysate, verfahren zu ihrer herstellung und arzneimittel, die diese hydrolysate enthalten
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
DE3515252C2 (de) * 1985-04-27 1994-02-24 Roehm Gmbh Verfahren zur Immobilisierung gelöster Eiweißstoffe
SE456136B (sv) * 1985-06-17 1988-09-12 Oncholab Ab Forfarande for framstellning av en med ett lipofilt biologiskt aktivt emne bemengd berare pa basis av rekonstituerat ldl (lagdensitetslipoprotein)
EP0206448B1 (de) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
AU6408586A (en) * 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems
US4783529A (en) * 1985-12-03 1988-11-08 Research Corporation Technologies Rapid synthesis of radiolabeled porphyrin complexes for medical application
US4849142A (en) * 1986-01-03 1989-07-18 Jupiter Technologies, Inc. Superplastic forging of zirconia ceramics
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4730936A (en) * 1986-10-10 1988-03-15 The United States Of America As Represented By The Secretary Of The Air Force Gas driven system for preparing large volumes of non-oxidized, pyridoxylated, polymerized stroma-free hemoglobin solution for use as a blood substitute
DE3636590A1 (de) * 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
WO1988006601A1 (en) * 1987-03-02 1988-09-07 Genex Corporation Gene repressors
GB8711614D0 (en) 1987-05-16 1987-06-24 Medical Res Council Proteins
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US5049493A (en) * 1987-10-23 1991-09-17 California Institute Of Technology Enhancement of cell growth by expression of a cloned hemoglobin gene
EP0319206A3 (de) * 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gen-Vermehrung
JP2561122B2 (ja) * 1988-04-13 1996-12-04 寳酒造株式会社 機能性ポリペプチド
EP0337799B1 (de) * 1988-04-14 1996-08-07 Incyte Pharmaceuticals, Inc. 14-Beta-gal Sauger-Lectin
US5137819A (en) * 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
IL87708A (en) * 1988-09-08 1994-04-12 Technion Inst For Research And Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5599907A (en) * 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
NL8901174A (nl) * 1989-05-10 1990-12-03 Het Hoofd Van De Afdeling Mili Hemoglobine-preparaat en gebruik daarvan.
ATE246246T1 (de) * 1989-05-10 2003-08-15 Baxter Biotech Tech Sarl Herstellung von hämoglobin und analogen davon in nicht-erythrozytzellen
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
JP2829397B2 (ja) * 1989-10-09 1998-11-25 寳酒造株式会社 フィブリン結合活性ポリペプチド
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
DE3938953A1 (de) * 1989-11-24 1991-05-29 Max Planck Gesellschaft Klonierung und expression des fuer die blut-hirn-schranke spezifischen proteins ht7
DK608589D0 (da) * 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
US5250665A (en) * 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
JP3426599B2 (ja) * 1991-11-08 2003-07-14 ヘモゾル インコーポレイテッド 薬物担体としてのヘモグロビン

Also Published As

Publication number Publication date
JP3426599B2 (ja) 2003-07-14
EP0611306B1 (de) 1998-07-08
AU665599B2 (en) 1996-01-11
EP0611306A1 (de) 1994-08-24
US5679777A (en) 1997-10-21
AU3132493A (en) 1993-06-07
CA2122717C (en) 2003-07-15
CA2122717A1 (en) 1993-05-13
JPH07500840A (ja) 1995-01-26
WO1993008842A1 (en) 1993-05-13
US5759517A (en) 1998-06-02
DE69226197T2 (de) 1999-02-11
ATE168014T1 (de) 1998-07-15

Similar Documents

Publication Publication Date Title
DE69226197D1 (de) Hämoglobine als arzneimittelabgabesystem
MY105482A (en) Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group.
EP0466816A4 (en) Method for enhancing transmembrane transport of exogenous molecules
EA199800946A1 (ru) Концентрированный препарат антител
DE69200490D1 (de) Tischgestell für medizinische Untersuchung.
ATA84882A (de) Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
SV1998000122A (es) Medicamentos ref. pu 3375/sv
NO905437L (no) Kateteranordning for hindring av blodlekkasje.
NO931766L (no) Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin
ES2181676T3 (es) Diagnosis y tratamiento de enfermedades autoinmunitarias.
DE68906153D1 (de) Humanes relaxinpraeparat.
WO1992019213A3 (en) Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
FI950062A (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
DK1229030T3 (da) Hydrolysefremmende, hydrofobe taxanderivater
DE68909409D1 (de) Heilmitteldosierung zur verabreichung an fische.
DE3882157D1 (de) Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen.
ATE56138T1 (de) Perfluorkohlenwasserstoffe als vehikel zur verabreichung von arzneimitteln.
SE8602743L (sv) Bruksferdiga injektionslosningar innehallande en antitumorantracyklinglykosid
SE9402880D0 (sv) New peptide derivatives
SE8404283D0 (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
ES2038064B1 (es) Instalacion portatil de vacunacion aviar.
IT1226072B (it) Soluzioni iniettabili pronte all'uso contenenti un glicoside antraciclinico antitumorale.
ES2111757T3 (es) Regiones antigenicas de complejos de particulas liberadas por tumores (tlp) y anticuerpos contra los mismos.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: BAXTER BIOTECH TECHNOLOGY S.A.R.L., NEUCHATEL, CH

8327 Change in the person/name/address of the patent owner

Owner name: HEMOSOL INC., ETOBICOKE, ONTARIO, CA

8327 Change in the person/name/address of the patent owner

Owner name: THERAPURE BIOPHARMA INC., MISSISSAUGA, ONTARIO, CA

8328 Change in the person/name/address of the agent

Representative=s name: REHBERG HUEPPE + PARTNER, 37073 GOETTINGEN

R071 Expiry of right

Ref document number: 611306

Country of ref document: EP